Diagnosing a Renal Mass Without Biopsy: Double FDA Acceleration for CAIX-Targeted 68Ga-NYM096 PET/CT

KEY FINDINGS

• Regulatory decision: On 19 August 2026 the FDA granted the investigational CAIX-targeted PET imaging agent 68Ga-NYM096 both Breakthrough Therapy and Fast Track designations.
• Target indication: Characterisation of indeterminate renal masses detected on CT or MRI and differentiation of clear cell renal cell carcinoma (ccRCC) from other subtypes.
• Preliminary study: In the open-label, multicentre study presented at ASCO 2026, 24 patients were evaluated (23 primary renal masses, 1 metastatic disease).
• Diagnostic performance: Patient-level sensitivity 100%, specificity 90%, accuracy 95.7%; in the primary renal mass subgroup 100% / 90% / 95.5%.
• Comparison with FDG: Mean SUVmax 52.2 versus 5.5 (p<0.001); tumour-to-kidney ratio 3.3 versus 1.7 (p<0.05).
• The road ahead: The developer announced that it plans to start phase 1 trials in the United States and China and that additional clinical data will be presented at the EANM 2026 Congress.

Why It Matters: The Problem of Diagnostic Uncertainty in Renal Masses

With the spread of cross-sectional imaging, renal masses are being detected ever more frequently and at ever smaller sizes, mostly incidentally. However, today's radiological methods cannot reliably distinguish whether a renal mass is malignant or benign, and if malignant which histological subtype it belongs to.

The clinical cost of this uncertainty is clear: a significant proportion of small renal masses removed surgically are reported as benign on pathology (angiomyolipoma, oncocytoma). In other words, some patients are exposed to an unnecessary partial or radical nephrectomy and its associated risks such as nephron loss, bleeding and urinary fistula. At the other extreme, the decision process is prolonged in patients who might be candidates for active surveillance or ablation because of diagnostic uncertainty.

Percutaneous renal biopsy fills this gap to some extent; but it is invasive, and rates of sampling error and non-diagnostic results are not negligible. Clear cell renal cell carcinoma (ccRCC) makes up approximately 70-80% of all renal cell carcinomas and differs markedly from other subtypes in its clinical behaviour, prognosis and response to systemic therapy; preoperative knowledge of subtype therefore directly affects the surgical decision.

Scientific Background: Why Is CAIX the Right Target?

Carbonic anhydrase IX (CAIX) is a transmembrane enzyme expressed on the cell surface. Inactivation of the VHL gene, the molecular signature of clear cell renal cell carcinoma, leads to constitutive activation of the hypoxia-inducible factor (HIF) pathway; as a result, CAIX is strongly expressed in almost all ccRCC cells while its expression is very low in normal kidney tissue and in non-ccRCC renal tumours. This selective expression profile makes CAIX effectively the equivalent for clear cell renal cell carcinoma of "PSMA in prostate cancer".

Why is the current standard inadequate? 18F-FDG PET/CT, the workhorse of routine oncological imaging, performs poorly in renal tumours: glucose transporter expression is variable in ccRCC cells and tumours often show low FDG uptake; in addition, because FDG is excreted through the kidneys, physiological activity in the collecting system makes assessment of primary renal lesions technically difficult.

ASCO 2026 Preliminary Data: Design and Results

The data underpinning the FDA's decision come from an open-label, multicentre preliminary study presented at the 2026 ASCO Annual Meeting (Abstract 4537). Population: 24 patients with primary or metastatic ccRCC; mean age 56.7 (SD 14.4). Some patients also underwent 18F-FDG PET/CT within one week before or after the 68Ga-NYM096 PET/CT, allowing the diagnostic performance of the two agents to be compared directly.

The most striking finding here is image contrast rather than the absolute diagnostic rates. A mean SUVmax reaching as high as 52.2 and a tumour-to-kidney ratio approximately twice that of FDG is a signal that could in practice markedly ease the discrimination of a lesion from physiological renal activity.

The Regulatory Framework: What Do These Designations Mean?

• Breakthrough Therapy: Granted to products with the potential to provide meaningful clinical superiority over existing approaches and to address an unmet medical need; it involves intensive FDA guidance in the development process and senior institutional involvement.
• Fast Track: Provides the opportunity for more frequent and structured interaction with the FDA during development; it can make the product eligible for accelerated approval, priority review and rolling review processes.
• The theranostic approach: The principle of using a binder directed to the same molecular target for imaging with a diagnostic radionuclide and for treatment with a therapeutic radionuclide.

The simultaneous granting of these two designations is a clear indication that the regulator regards non-invasive subtype determination in renal masses as an unmet medical need. A critical reminder is nevertheless required: these designations do not mean approval; they are merely administrative tools accelerating the development and review process.

The Competitive Landscape: Where Are We in CAIX-Targeted Imaging?

68Ga-NYM096 is not the only candidate in this field. The most mature programme is the antibody-based 89Zr-DFO-girentuximab, evaluated in the phase 3 ZIRCON trial. In ZIRCON, an average across three independent readers reported sensitivity of 85.5%, specificity of 87% and a positive predictive value for ccRCC of 92.9%; performance was maintained even in the cT1a (≤4 cm) small mass subgroup. However, the biologics licence application for this agent resulted in a Complete Response Letter on the grounds of deficiencies in the manufacturing and quality control (CMC) package.

The fundamental difference between the two approaches is the radionuclide and the size of the molecule: while a zirconium-89 labelled antibody takes days to accumulate sufficiently in the tumour, gallium-68 labelled small molecule agents allow same-day imaging thanks to their approximately 68-minute half-life. This is a practical advantage in terms of patient comfort, workflow and the timetable of surgical planning.

Implications for Clinical Practice

1. Avoiding unnecessary surgery

A non-invasive and highly accurate subtype determination carries the potential to reduce the rate of unnecessary nephrectomy in benign lesions. This may be decisive for a nephron-sparing strategy particularly in patients with a solitary kidney, chronic renal failure or bilateral masses.

2. Planning robotic partial nephrectomy

Confirming at a molecular level before surgery that the tumour is ccRCC could place decisions on surgical margin strategy, lymph node assessment and the extent of resection on a more rational footing. Equally, it could support a preference for enucleation or surveillance in lesions that appear biologically indolent.

3. Selecting candidates for active surveillance and ablation

Active surveillance is a safe option in appropriate patients with small renal masses; but the greatest obstacle is the anxiety created by diagnostic uncertainty. An imaging method that reliably establishes the subtype could increase both the psychological and the clinical reliability of a surveillance decision.

4. Staging and assessment of recurrence

High tumour-to-background contrast could contribute to the detection of small metastatic foci that remain equivocal on conventional imaging and of postoperative local recurrences. However, separate and prospective validation is needed for these indications.

Limitations of the Data: A Cautious Reading Is Essential

• The sample is very small: Only 24 patients. Reporting 100% sensitivity in a series of this size means a wide confidence interval; this rate should be expected to fall in larger series.
• Level of publication: The data were presented as a congress abstract, not as a peer-reviewed full-text article.
• Single-arm design: The study is not randomized and details of reader blinding are limited.
• Early development stage: The agent has not yet entered a broad registrational phase 3 process.
• The limits of the comparator: FDG PET is not in any case the standard diagnostic method for renal masses; the truly meaningful comparison will be against contrast-enhanced CT/MRI and existing CAIX-targeted agents.

Conclusion

The FDA's granting of both Breakthrough Therapy and Fast Track designations to 68Ga-NYM096 is a strong signal that the age of molecular imaging in kidney cancer is accelerating. We have seen at first hand how PSMA PET/CT fundamentally reshaped staging and treatment decisions in prostate cancer; CAIX-targeted agents are a candidate for a similar transformation in clear cell renal cell carcinoma.

However, the data we have today consist of a preliminary study of 24 patients. The true value of the agent will emerge in larger, prospective, pathology-confirmed and multicentre studies, particularly in the small and indeterminate renal masses where the diagnostic dilemma is sharpest. We must follow this programme closely - while maintaining current diagnostic and surgical standards until the evidence matures.

References

• Clarke H. FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent. Urology Times, 19 August 2026.
• Norroy Bioscience Co. Ltd. NORROY BIOSCIENCE Granted FDA Breakthrough Therapy and Fast Track Designations for Kidney Cancer Imaging Product. Press statement, 19 August 2026.
• Xue Y, Yu W, Wu T, et al. [68Ga]Ga-NYM096 PET/CT in patients with primary and metastatic clear cell renal cell carcinoma: A preliminary study. J Clin Oncol. 2026;44(suppl 16; abstr 4537).
• Targeted Oncology. Phase 3 ZIRCON Study Shows High Sensitivity/Specificity With 89Zr-DFO-girentuximab in ccRCC.
• Urology Times. FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC.